Fundraising FoxVersant Ventures — 2019 Investments
6 investments dated 2019 · listed companies and verified rows first · show all
Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.
BiotechHealthtech
Carmine Stengone(President and Chief Executive Officer)inPeter T. Slover(Chief Financial Officer)inDaniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in
Co-investorsHadean VenturesRed Tree VentureSamsara BioCapitalCasdin CapitalFranklin TempletonJJDC+1 more
Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.
BiotechHealthtechPhiladelphia, US
William Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)Stephen Squinto(Executive Officer, Director)in
BoardPatrick Heron(Director)inCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)
Co-investorsFrazier Life SciencesAccess BiotechnologyFrazier Healthcare PartnersLilly Asia VenturesNew Leaf Venture PartnersOrbiMed+2 more
BiotechNew York, US
Michael Burgess(Executive Officer)Jose Manuel Otero(Executive Officer)Robert Gould(Director)inJane Henderson(Executive Officer)inStefan Larson(Director)Patrick Machado(Director)
Board seatBrad BolzonJerel Davis· per SEC Form D
Co-investorsBrace PharmaF-Prime CapitalFACIT (Fight Against Cancer Innovation Trust)Foothill VenturesVenture OntarioOrbiMed+1 more
Nuvaira develops the dNerva Lung Denervation System, a catheter-based device used in a one-time, outpatient bronchoscopic procedure that disrupts pulmonary nerve input to treat chronic obstructive pulmonary disease (COPD).
HardwareHealthtechMedical DevicesMinneapolis, US
Martin Mayse(Founder)inSteve Dimmer(Founder)inDennis Wahr(President & CEO)inLisa Flaherty(Chief Strategy Officer)inSteve Sathre(Vice President of Finance)inSteve Paidosh(Vice President of Operations)
Co-investorsWindham Capital PartnersEndeavour VisionLightstone VenturesMorgenthalerQiming Venture PartnersRichard King Mellon Foundation+2 more
A healthcare company that develops and supplies medicines, including new and more affordable therapies, aiming for reliable supply of needed treatments.
BiotechHealthtechSan Francisco, US
Jeffrey Nau(Executive Officer, Director)inMark A. Murray(Executive Officer, Director)D. Michael Ackermann(Director)
BoardWilliam J Link(Director)Ali Behbahani(Director)in
Co-investorsFlying L PartnersNew Enterprise Associates (NEA)Versant Venture AIV HoldingsVida Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.